| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥486.3B | ¥481.2B | +1.1% |
| Operating Income | ¥56.5B | ¥60.5B | -6.7% |
| Ordinary Income | ¥58.3B | ¥62.0B | -6.0% |
| Net Income | ¥34.1B | ¥40.0B | -14.8% |
| ROE | 7.3% | 9.4% | - |
FY2026 Q3 cumulative results show revenue of 486.3 billion yen (YoY +1.1%), operating income of 56.5 billion yen (YoY -6.7%), ordinary income of 58.3 billion yen (YoY -6.0%), and net income of 34.1 billion yen (YoY -14.8%). The company achieved modest revenue growth but experienced profit decline across all levels. Operating margin contracted approximately 100 basis points from 12.6% to 11.6%, driven by increased selling, general and administrative expenses despite maintaining a healthy gross profit margin of 45.0%. The gap between ordinary and net income reflects a tax burden with an effective tax rate of approximately 35.2% and special losses of 563 million yen. Q3 standalone quarterly revenue reached a record high of 189.6 billion yen. Full-year guidance projects revenue of 700 billion yen (+4.3%), operating income of 95 billion yen (+7.8%), and net income of 65 billion yen, indicating expected recovery in the fourth quarter.
Revenue increased 1.1% YoY to 486.3 billion yen, driven by robust demand in the Measuring Instruments segment in Japan and China, recovery in DSP equipment profitability, and special demand projects in the Medical and Health System segment. The Medical and Health System segment contributed to growth with sales of 189 billion yen (+5.4%), supported by strong US medical equipment demand and foreign exchange tailwinds. However, the Semiconductor-Related segment declined 5.7% to 84 billion yen due to continued demand adjustment in the semiconductor market.
Operating income decreased 6.7% to 56.5 billion yen despite higher revenue, primarily due to increased SG&A expenses and higher sales costs in the Medical and Health System segment. The US tariff impact and intensified sales activities in the Americas and Europe elevated cost structures. Operating margin compressed from approximately 12.6% to 11.6%, reflecting a 100 basis point deterioration. The Measuring Instruments segment demonstrated operational efficiency improvement with operating income growth of 14.1% despite flat revenue, while the Medical and Health System segment experienced a 15.5% decline in operating income despite revenue growth, indicating margin pressure.
The gap between operating income (56.5 billion yen) and ordinary income (58.3 billion yen) was modest at 1.8 billion yen, attributable to non-operating income of 6.7 billion yen (including foreign exchange gains and interest income) partially offset by non-operating expenses of 4.9 billion yen. This suggests limited extraordinary factors at the ordinary income level.
The larger gap between ordinary income (58.3 billion yen) and net income (34.1 billion yen) of 24.2 billion yen (41.5% reduction) reflects significant tax burden and special losses. Special losses totaled 563 million yen, while the effective tax rate of 35.2% significantly reduced profit after tax. The tax coefficient (NI/EBT) of 0.644 indicates approximately 35.6% in combined tax and other charges, which is elevated compared to typical corporate tax rates.
Non-recurring factors include special losses of 563 million yen, though specific composition was not detailed. The substantial increase in goodwill from 3 million yen to 68 million yen (+2,166.7%) suggests potential M&A activity or subsidiary integration, introducing future impairment risk.
This represents a revenue up, profit down pattern, characterized by top-line growth offset by operating expense increases, elevated tax burden, and non-recurring special losses.
The company operates three primary business segments: Medical and Health System (core business), Measuring Instruments, and Semiconductor-Related.
Medical and Health System segment generated revenue of 189 billion yen (+5.4% YoY) and operating income of 29 billion yen (-15.5% YoY), representing the largest revenue contributor. Within this segment, Japan contributed sales of 125 billion yen with operating income of 24 billion yen (operating margin approximately 19.1%), Asia and Oceania contributed sales of 62 billion yen with operating income of 2 billion yen (margin 2.5%), Americas contributed sales of 79 billion yen with operating income of 1 billion yen (margin 1.0%), and Europe contributed sales of 76 billion yen with operating income of 3 billion yen (margin 4.4%). The segment experienced revenue growth driven by strong US medical equipment demand and special health equipment projects, but profitability was pressured by US tariffs and increased sales costs, particularly in the Americas region which showed the lowest operating margin. This core business represents a significant portion of consolidated revenue but exhibited deteriorating profitability despite volume growth.
Measuring Instruments segment recorded revenue of 213 billion yen (+0.3% YoY) and operating income of 16 billion yen (+14.1% YoY), demonstrating strong operational efficiency improvement. Within this segment, Japan contributed sales of 159 billion yen with operating income of 13 billion yen (margin 8.1%), Asia and Oceania contributed sales of 69 billion yen with operating income of 5 billion yen (margin 6.5%), Americas contributed sales of 36 billion yen with operating loss of -2 billion yen (negative margin), and Europe contributed sales of 5 billion yen with operating income of 0.2 billion yen (margin 3.8%). The segment benefited from robust demand in Japan and China for weighing instruments and successful DSP equipment profitability improvement initiatives. Operating margin improved significantly due to cost reduction measures, partially offsetting US tariff impacts. The Americas subsegment remains unprofitable, warranting monitoring.
Semiconductor-Related segment (Japan only) generated revenue of 84 billion yen (-5.7% YoY) and operating income of 28 billion yen (-9.0% YoY), with an operating margin of approximately 33.5%, the highest among all segments. The decline reflects continued demand adjustment in the semiconductor market, though performance is tracking within management expectations. The segment launched new product HSS-1000 and completed a new factory, positioning for future recovery. Despite near-term headwinds, this segment maintains the strongest profitability profile.
Segment margin disparity is material: Semiconductor-Related operates at approximately 33.5% margin, Medical and Health System Japan at 19.1%, Measuring Instruments Japan at 8.1%, while Americas operations in both Medical and Measuring segments show weak or negative margins (1.0% and negative, respectively). Geographic expansion in the Americas represents a significant profitability challenge, with sales cost increases outpacing revenue growth. The core Medical and Health System business drove revenue growth but was the primary contributor to profit decline, making margin recovery in this segment critical to overall performance improvement.
Profitability: ROE 7.3% (below the manufacturing industry median of 5.0% but remains modest), ROA 3.3% (in line with industry median of 3.3%), operating margin 11.6% (above industry median of 8.3%), net profit margin 7.0% (above industry median of 6.3%). The company maintains superior operating and net margins compared to industry peers, though ROE remains subdued due to conservative financial leverage.
Cash Quality: Operating cash flow details not disclosed in XBRL data, limiting assessment of OCF/Net Income ratio. Cash and deposits of 125.6 billion yen provide liquidity buffer, though working capital deterioration flags (receivables and inventory turnover concerns) suggest potential cash generation headwinds. Free cash flow cannot be calculated without operating CF and capex details.
Investment: Capex and depreciation details not fully disclosed, limiting capex/D&A ratio assessment. The completion of a new semiconductor factory indicates ongoing capital investment in growth capacity.
Financial Health: Equity ratio 64.4% (in line with industry median of 63.8%), current ratio 231.4% (below industry median of 284%), financial leverage 1.55x (slightly above industry median of 1.53x). The balance sheet structure is conservative with strong equity base, though the extremely high short-term debt ratio of 98.3% introduces refinancing risk. Short-term borrowings of 114.8 billion yen are largely covered by cash holdings (coverage ratio 1.09x), but the maturity mismatch between assets and liabilities warrants monitoring.
Working Capital Efficiency: Receivables turnover days and inventory turnover days show deterioration warnings per AI analysis, though specific figures not provided in XBRL. Industry benchmark for receivables is 82.9 days (median) and inventory 108.8 days (median), suggesting the company may be trending above these levels. Operating working capital turnover deterioration represents a key risk to cash generation quality.
Operating cash flow, investing cash flow, and financing cash flow details are not disclosed in the provided XBRL data, preventing comprehensive cash flow analysis.
Cash position: The company holds cash and deposits of 125.6 billion yen (up from prior period), representing 17.4% of total assets. This provides a substantial liquidity buffer against short-term borrowings of 114.8 billion yen, resulting in a net cash position of approximately 10.8 billion yen.
Investing activity: The completion of a new semiconductor factory and launch of new product HSS-1000 indicate ongoing capital investment, though specific capex amounts are not disclosed. Goodwill increased significantly from 3 million yen to 68 million yen (+2,166.7%), suggesting potential M&A or subsidiary integration activity, though details are not provided.
Financing activity: Long-term borrowings decreased sharply from 12.7 billion yen to 2.0 billion yen (-83.9%), indicating debt repayment or refinancing into short-term facilities. Dividend payments are estimated at approximately 4.0 billion yen based on 40 yen per share annual dividend and share count, representing a payout ratio of 32.8%.
Cash generation quality: Cannot be definitively assessed without operating cash flow data. However, the working capital deterioration warnings (extended receivables and inventory days) suggest that reported net income may not be fully converting to cash. The operating cash flow to net income ratio would be critical to monitor, with a target above 1.0x indicating healthy cash-backed earnings.
Overall assessment: Adequate liquidity is maintained through cash holdings, but the absence of detailed cash flow data and working capital concerns prevent a strong positive assessment. Cash generation warrants monitoring, particularly given the profit margin pressure and working capital cycle extension.
Ordinary income of 58.3 billion yen declined 6.0% YoY, closely tracking operating income decline of 6.7%, indicating core business profit deterioration. Net income of 34.1 billion yen declined 14.8% YoY, a significantly larger decrease than ordinary income, driven by special losses and elevated tax burden.
Non-recurring items: Special losses totaled 563 million yen (approximately 1.2% of revenue), though specific composition is not detailed. These losses are non-recurring in nature and should be excluded when assessing sustainable earnings power. Additionally, goodwill increased from 3 million yen to 68 million yen (+2,166.7%), suggesting M&A activity that may introduce future amortization or impairment charges.
Tax burden: The effective tax rate of approximately 35.2% is elevated, with income taxes of approximately 18.6 billion yen on pre-tax income of 52.7 billion yen. This tax rate appears high relative to Japan's statutory corporate tax rate and may reflect non-deductible items or regional tax variations. The tax coefficient (net income/pre-tax income) of 0.644 indicates approximately 35.6% in combined tax and other charges, materially impacting net earnings.
Non-operating items: Non-operating income of 6.7 billion yen and non-operating expenses of 4.9 billion yen netted to a positive contribution of 1.8 billion yen. Non-operating income includes foreign exchange gains and interest income, which can be volatile and are not core business earnings. At approximately 1.4% of revenue, non-operating items are not material but should be monitored for sustainability.
Accruals concern: Working capital deterioration flags (extended receivables collection days and inventory holding days) suggest that reported earnings may not be fully converting to cash. When operating cash flow trails net income, it indicates earnings quality concerns due to aggressive revenue recognition, inventory buildup, or collection challenges. Without disclosed operating cash flow data, this cannot be quantified, but the working capital warnings represent a significant earnings quality risk.
Core earnings assessment: Adjusting for special losses of 563 million yen and elevated tax burden, normalized net income would be approximately 34.7 billion yen at a standard 30% tax rate, compared to reported 34.1 billion yen. The primary earnings quality concern is not one-time items but rather the structural increase in SG&A expenses, working capital deterioration, and sustainability of foreign exchange gains. The 45.0% gross margin remains healthy, but operating leverage is deteriorating as SG&A growth outpaces revenue growth.
Overall earnings quality assessment: Moderate quality with concerns. While gross profitability remains strong and non-recurring items are limited, the combination of working capital deterioration, elevated SG&A spending, and potential cash conversion issues indicate earnings quality warrants monitoring.
Full-year guidance projects revenue of 700 billion yen (+4.3% YoY), operating income of 95 billion yen (+7.8% YoY), ordinary income of 94 billion yen (+5.0% YoY), and net income of 65 billion yen (representing recovery from Q3 cumulative results). Dividend guidance is 25 yen per share annually, though interim results indicate 40 yen (20 yen interim + 20 yen year-end expected).
Progress rate analysis: Q3 cumulative results represent 9 months (75% of fiscal year). Revenue achievement is 69.5% of full-year guidance (486.3B/700B), tracking 5.5 percentage points below the standard 75% progress rate. Operating income achievement is 59.5% (56.5B/95B), tracking 15.5 percentage points below standard. Net income achievement is 52.2% (34.1B/65B), tracking 22.8 percentage points below standard. This significant lag indicates management expects a very strong Q4 performance.
Q4 implied performance: To achieve full-year guidance, Q4 standalone must deliver revenue of 213.7 billion yen (representing 30.5% of full-year revenue in a single quarter), operating income of 38.5 billion yen (operating margin 18.0%), and net income of 30.9 billion yen. This would represent substantial sequential improvement, particularly in operating margin which ran at 11.6% for the Q3 cumulative period. Q4 operating income would need to be 68% higher than the average quarterly run-rate of Q1-Q3.
Feasibility assessment: The Q3 standalone quarter achieved record revenue of 189.6 billion yen with improved trends, demonstrating sequential momentum. However, achieving 18% operating margin in Q4 (versus 11.6% cumulative) requires significant operating leverage improvement, implying either substantial SG&A cost reduction, favorable product/regional mix, or one-time gains. Management commentary indicates US tariff response measures (pricing optimization, supply chain efficiency) and continued DSP equipment profitability improvement are underway, which could support margin expansion.
Key drivers for guidance achievement: (1) Sustained strong performance in Medical and Health System segment with improved Americas profitability, (2) semiconductor market demand recovery or new product HSS-1000 contribution, (3) continued Measuring Instruments efficiency gains, (4) successful mitigation of US tariff impacts through pricing actions, (5) favorable foreign exchange rates (assumed USD/JPY 140.00), and (6) operating expense control.
Revision status: No revision to full-year guidance has been announced. The significant progress lag, particularly in profitability metrics, suggests either high confidence in Q4 recovery or potential risk of future downward revision if improvement does not materialize. Investors should monitor Q4 order trends and margin trajectory closely.
Dividend policy: The company has declared an interim dividend of 20 yen per share and indicates year-end dividend expectation of 20 yen per share, totaling 40 yen annually. However, full-year guidance shows dividend of 25 yen per share, creating some inconsistency in communication. Based on Q3 cumulative net income of 34.1 billion yen and assuming 40 yen total annual dividend, the payout ratio is approximately 32.8%, which is conservative and sustainable.
Dividend sustainability: With cash and deposits of 125.6 billion yen and estimated dividend payment of approximately 4.0 billion yen annually (based on 40 yen per share), dividend coverage from cash alone exceeds 31x. The 32.8% payout ratio is well below the 60% sustainability threshold, indicating dividend is sustainable from earnings. However, without disclosed operating cash flow data, true cash-based dividend coverage cannot be assessed. Working capital deterioration may constrain cash generation despite adequate reported earnings.
Share buyback: No share buyback program is mentioned in the provided materials. Total shareholder return is limited to dividends only at this time.
Capital allocation: The conservative 32.8% payout ratio and strong cash position suggest capacity for increased shareholder returns, either through dividend increases or initiation of buybacks. However, management appears to be prioritizing investment in growth (new semiconductor factory, geographic expansion) and maintaining financial flexibility given the high short-term debt ratio.
Year-over-year comparison: Prior period dividend information is not provided, preventing assessment of dividend growth trends. The maintenance of dividend at 40 yen per share (assuming consistency with guidance of 25 yen represents the minimum) despite 14.8% net income decline demonstrates commitment to shareholder returns.
Total return ratio: Based on dividends only (no buybacks), the total return ratio equals the payout ratio of approximately 32.8%, which is conservative for a company with 64.4% equity ratio and moderate growth profile.
Near-term catalysts:
Long-term catalysts:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 7.3% vs. industry median 5.0% (above median, ranking in upper half of manufacturing sector), ROA 3.3% vs. industry median 3.3% (in line with median), operating margin 11.6% vs. industry median 8.3% (above median by 330 basis points, indicating superior operational efficiency), net profit margin 7.0% vs. industry median 6.3% (above median by 70 basis points).
Financial Health: Equity ratio 64.4% vs. industry median 63.8% (in line with peers, indicating conservative capital structure), current ratio 231.4% vs. industry median 284% (below median by approximately 50 percentage points, suggesting relatively lower short-term liquidity despite absolute ratio appearing healthy), financial leverage 1.55x vs. industry median 1.53x (slightly above median, consistent with equity ratio positioning).
Efficiency: Asset turnover 0.673x vs. industry median 0.58x (above median, indicating superior asset utilization despite working capital concerns), operating working capital turnover days not precisely disclosed but flagged warnings suggest above industry median of 108 days, inventory turnover days flagged as concern versus industry median of 109 days, receivables turnover days flagged as concern versus industry median of 83 days.
Growth: Revenue growth 1.1% vs. industry median 2.7% (below median, indicating slower top-line expansion), EPS growth -14.8% (net income decline) vs. industry median 6% growth (significantly underperforming peers due to profit margin pressure).
Overall Assessment: The company demonstrates above-average profitability margins and asset efficiency relative to manufacturing sector peers, supported by strong equity position. However, revenue growth lags industry median and recent earnings growth is negative, driven by operating expense increases and working capital deterioration. The company's margin advantage partially offsets volume growth challenges, but recent profit trajectory suggests margin defense is under pressure. Current ratio below industry median despite absolute adequacy reflects the concentrated short-term debt structure (98% short-term debt ratio). Focus areas for improvement include revenue growth acceleration, operating expense control to restore margin expansion, and working capital cycle optimization.
Industry: Manufacturing sector (98 companies in reference dataset), Comparison: FY2025 Q3 median and interquartile range, Source: Proprietary analysis of publicly available earnings data.
Operational Risks:
Financial Risks:
Strategic Risks:
Key Takeaways from Earnings:
Margin defense challenge amid mixed segment performance: The company maintains industry-leading operating margin of 11.6% (above sector median of 8.3%) and strong gross margin of 45.0%, but experienced 100 basis point margin compression year-over-year despite modest revenue growth. This pattern indicates operating leverage deterioration, with SG&A expense growth outpacing revenue growth. The core Medical and Health System segment demonstrated the concerning dynamic most clearly - 5.4% revenue growth paired with 15.5% operating income decline. Geographic expansion costs in the Americas (1.0% margin in Medical, negative margin in Measuring Instruments) and US tariff impacts are structural headwinds requiring sustained management attention. The Measuring Instruments segment's success in improving operating income 14.1% on flat revenue through DSP equipment efficiency initiatives demonstrates that margin recovery is achievable through operational excellence, providing a potential template for other segments. However, full-year guidance implies dramatic Q4 margin expansion to 18.0% from 11.6% cumulative, creating significant execution risk. The earnings reveal a company at an inflection point between sustaining premium margins through efficiency and allowing growth investment costs to compress profitability.
Working capital and cash generation quality require urgent attention: Multiple AI analysis warnings flag deterioration in receivables collection days and inventory turnover days beyond normal industry levels (sector medians: 83 days receivables, 109 days inventory). This working capital cycle extension indicates that reported earnings are not fully converting to cash, raising earnings quality concerns despite adequate absolute profitability. The issue is compounded by balance sheet structure featuring 98.3% short-term debt concentration (114.8 billion yen short-term borrowings versus only 2.0 billion yen long-term) following an 83.9% reduction in long-term debt. While current cash holdings of 125.6 billion yen provide adequate coverage (1.09x short-term debt), the combination of constrained cash generation from operations and refinancing concentration creates vulnerability. If working capital inefficiency persists, the company may face pressure funding growth capex (new semiconductor factory completed), dividends (approximately 4 billion yen annually), and debt service solely from internal cash flow. The absence of disclosed operating cash flow data prevents quantification but the structural indicators suggest this represents the most critical near-term financial risk requiring investor monitoring.
Semiconductor and medical long-term positioning offset near-term cyclical pressure: Despite near-term headwinds, the company's strategic positioning across secular growth markets provides meaningful long-term value drivers. The Semiconductor-Related segment, though currently experiencing demand adjustment (-5.7% revenue), maintains exceptional 33.5% operating margin and has established new product (HSS-1000) and capacity (new factory completion) for AI-driven semiconductor manufacturing demand recovery. Management explicitly targets AI-related applications, positioning for multi-year industry expansion. The Medical and Health System segment, despite current margin pressure, addresses global aging demographics and medical DX trends with consistent demand visibility. The completion of Q3 standalone record revenue of 189.6 billion yen and sequential momentum suggests cyclical trough may be forming. However, realizing this long-term potential requires near-term execution on margin recovery, particularly in Americas geographic expansion where current profitability is weak to negative. The Measuring Instruments segment's linkage to carbon neutrality and industrial digitalization trends provides additional diversification. The earnings data reveal a company with sound long-term strategic positioning but facing a critical 12-18 month period to demonstrate operational execution, working capital discipline, and profitability sustainability before secular tailwinds fully materialize.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
For A&D HOLON Holdings’ FY2026/3 Q3 results, revenue was 486億円 (YoY +1.1%) and operating profit was 56億円 (-6.7%), reflecting slight top-line growth with lower earnings. The Semiconductor-related Business saw lower revenue and profit due to the continued demand-adjustment phase, while the Measurement and Weighing Instruments Business posted higher profit driven by resilient demand in Japan and China and improved profitability of DSP equipment. The Medical and Health Equipment Business achieved higher revenue on special-demand projects and FX tailwinds, but lower profit due to U.S. tariffs and increased selling costs. The full-year outlook calls for revenue of 700億円 (+4.3%) and operating profit of 95億円 (+7.8%), implying higher revenue and profit. Taking into account the impact of U.S. tariffs, the company plans to pursue price optimization tailored to local markets and to enhance supply chain efficiency.
Standalone Q3 revenue reached a record-high 189.6億円 (YoY +2.9%). In the Semiconductor-related Business, the new product HSS-1000 was announced and a new plant was completed. Profitability enhancement measures for DSP equipment in the Measurement and Weighing Instruments Business proved effective, lifting operating profit by +14.1%. The Medical and Health Equipment Business saw higher revenue on continued strength in U.S. medical devices and special-demand projects in health devices. Full-year dividend maintained at 40円 (interim 20円, year-end 20円 assumed).
The Semiconductor-related Business expects medium- to long-term market expansion, centered on AI-related demand, and will steadily advance new product development. The Medical and Health Equipment Business anticipates medium- to long-term demand growth backed by progress in medical DX and global population aging, focusing on expanding global market coverage and sales in priority regions. The Measurement and Weighing Instruments Business will continue development and production-capacity investments amid advances in carbon neutrality and digitalization, and develop new products for targeted markets.
Given the impact of U.S. tariffs, the company will promote price optimization tailored to local markets and enhance supply chain efficiency. The Semiconductor-related Business is progressing within expectations and will steadily develop new products aligned with emerging demand. For Measurement and Weighing Instruments and Medical and Health Equipment, the company will closely monitor demand trends by region and product while enforcing cost control accompanying strengthened sales activities. The company expects higher revenue and profit for the full year and aims for sustainable growth.
Market launch of the new HSS-1000 in the Semiconductor-related Business and production ramp-up at the new plant. Expand global market coverage for the Medical and Health Equipment Business and strengthen sales activities in priority regions (the Americas and Europe). Continue profitability enhancement measures in the Measurement and Weighing Instruments Business (improve profitability of DSP equipment). In response to the impact of U.S. tariffs, promote local-market price optimization and supply chain efficiency. Leverage long-cultivated measurement technologies to contribute to a sustainable society by advancing carbon neutrality, medical care, healthy longevity, and a digital society.
Risk of a prolonged demand-adjustment phase in the semiconductor market. Earnings pressure from U.S. tariffs and the effectiveness of countermeasures. Ongoing cost increases associated with strengthening sales activities in the Americas and Europe in the Medical and Health Equipment Business. Impact of exchange rate fluctuations on results (assumed rate: 1 USD = 140円, 1 RUB = 1.60円). Potential variability in earnings forecasts due to economic trends in Japan and globally, and progress in new technology development.